

# **Community Engagement Workshop 1: Future of evidence synthesis in Cochrane – an introduction**

## **Breakout group feedback**

### **Global Challenges**

#### **What do you see as the most important challenge?**

- Some clinical areas are missing and some seem very broad
- Areas that are poorly-funded or under-researched could be left behind – is this okay with Cochrane?
- How do we make a global framework work when priorities vary so much nationally and regionally?
- It was not clear how the global challenges framework informs the work of the Cochrane evidence synthesis units.

#### **What do you see as the most important opportunity?**

- The global framework may be a way to advocate for Cochrane with funders

#### **Can you propose an alternative?**

- Better model is to build on the local knowledge in CRGs to prioritize

### **Stakeholders**

#### **What do you see as the most important challenge?**

- Clarity on who are our stakeholders – users of content, funders of content?
- Better understanding needs of stakeholders
- Improve timing to meet needs – rather than having to rely on lower quality evidence
- Cochrane seeking perfection!!!
- Do we know how many patients, clinicians, policy makers are reading reviews?
- Cochrane doesn't make recommendations – stakeholders want to know what to do

#### **What do you see as the most important opportunity?**

- New production model could be interdisciplinary & co-production focussed
- Provide an opportunity to work better with our stakeholders - stakeholders pose questions and Cochrane to respond to these

#### **Can you propose an alternative?**

- Focus on main outcomes (to improve speed)
- Work with Guideline panels to make recommendations
- Dialogue with communities of stakeholders – needs, questions, priorities,
  - Health ministries – funders
  - Patients
  - Guideline developers
  - Clinicians
  - Educators
  - Researchers

## Review development

### What do you see as the most important challenge?

- Capacity – lack of funding. How do achieve this? Size of unit?
- Guidance on nature of products needed to publish.
- Struggle with basic Rx reviews – how will the new units support greater complexity?
- Submission quality & volume
- Coverage – can it continue to aspire to comprehensive coverage?
- Timely input of topic expertise and access to topic experts?
- **These new groupings are so broad**
- **Support** - When we say support authors what is the scope? What does it look like? 1 to 1? Include training too?
- **Expertise** - Specific content expertise may be missed; especially important for junior authors (next generation of Cochrane), picking questions. CRGs also are knowledgeable in commissioning author team (diverse in people, expertise, and geo location)
- **Funding** - Is this the best way to get funding? Should they be reorganized into Conditions? Organized based on funding could be attracted? What about groups that have secured funding – will this cause them to lose funding? Isn't being specific better to attach funding?

### What do you see as the most important opportunity?

- Standard setting – across systematic reviews. External regulatory body?
- Need to explore ways to innovate membership & contribution of topic expertise
- **New and exciting ways to produce evidence, more usable, get away from long reviews**
- **Who are we serving?** Who are the end-user of reviews? Maybe responsive to the funders. How does PLS fit into business model? How do all the pieces fit together?
- **Have a scope of what we can do and then negotiate what will be delivered based on funding for each review** – do they want a PLS, do they want a Cochrane Corner, podcast, do they need a background section, ect. Have 'core' items and then nice to haves, and extras.

### Can you propose an alternative?

- Need to keep contact editors involved – priority setting & recommendations for authors & feedback
- 'Local voice' – need to explore ways to do this
- **Look at how the Canadian groups dealt with funding issues, and the US** – they have gone through this about 10 years. Look to how they dealt with it.

## Cochrane Evidence Synthesis Units

### What do you see as the most important challenge?

- How do we keep content specialists on board if the Cochrane evidence synthesis units are multidisciplinary? People's passion lies with their content area, so does Cochrane risk losing a lot of their clinical/content expert community?
- How would we reposition current CRG members within Cochrane evidence synthesis units i.e., ISs, MEs, systematic reviewers? There would still be a need for project management, but not the need for the same editorial process staff. How do we ensure we don't lose these skilled staff?

### **What do you see as the most important opportunity?**

- Cochrane's asset is its breadth and depth of expertise and diversity of people in community. Units could have embedded methods, content, and consumer expertise.
- There could be a board of content experts who can oversee prioritisation/production of reviews in their areas, providing an opportunity for cross-disciplinary collaboration.

### **Can you propose an alternative?**

- A more phased approach – the groups that still have funding can continue and gradually integrate into a different model as it grows and develops, mitigating risk attached to a sudden transition.

## **Central Editorial Service**

### **What do you see as the most important challenge?**

- Sign-off responsibility clinical e.g., paediatrician signing off a dementia review isn't feasible
- Losing content expertise (Co-Eds specifically).
- Knowing topic areas e.g., peer-reviewers who might be favourable toward a manuscript or against it.
- Volunteer author model (life changes, house moves, babies etc.) – need process for how authors should start and be supported.
- Even funded authors don't always deliver.
- Dividing point between the evidence synthesis units and Central Editorial Service – where on the continuum does this come?
- 'Free for all' – authors submitting on any topic, without co-ordination via the CRGs.

### **What do you see as the most important opportunity?**

- Ensuring consistency for authors.
- Being able to access methodologists for sign off.
- Contractual understanding with authors.
- Having everything go through Central Editorial Service could standardise processes.

### **Can you propose an alternative?**

- Bank of clinical experts working together
- Different intensities of author support in the Evidence Synthesis Units

## **Direct pathway to publication**

### **What do you see as the most important challenge?**

- Quality control still important, how can we maintain quality and how that would be funded.
- Would the author teams be expected to provide their own funding?
- Capacity within central service. Will the editorial efficiency pilot be expanded?
- Is there a need for this? Are there already requests for this?

### **What do you see as the most important opportunity?**

- More flexibility and potential for topics that fall outside remit of Cochrane evidence synthesis units to be published; attract other author teams and keep talent involved within Cochrane.
- Maintain another process to ensure priority reviews get published. Would this model ensure reviews get published in a timelier process?
- For CRGs with stable funding might this be a pathway for some of those groups? They may then remain as a recognisable entity and publish reviews and remain funded

**Can you propose an alternative?**

- To have a direct pathway to publication within each synthesis unit
- This depends on the model proposed, e.g., groups outside of UK

**Publication**

**What do you see as the most important challenge?**

- Fundamental need to sustain published output through transition period.
- Challenge to get the right skills/technologies for new formats or content types.
- If the output is shorter/simpler, could the whole editorial process be reduced?
- Education needed to bring the audience with us if we move away from familiar offering.
- For new review types, is Cochrane able to commit to standards, and can guidance and handbook be more living?

**What do you see as the most important opportunity?**

- Shorter, more packaged, formats; data visualisation for text-heavy sections
- Intermediate format (preferably automated) between 2-page summary and 200-page review
- Use of filtering (such as PICO) to focus in on elements of relevance
- New ways of presenting living content, less tied to journal model (wiki-like?), alongside surveillance
- Scoping in a format that doesn't need to be a 'review' type - scoping work often not published

**Can you propose an alternative?**

- Can outputs/products focus more directly on different users' needs? More accessible and directly meeting user needs
- Some interactive elements, or visible annotations